NRG Oncology/GOG Studies
- The authors regret that there was some conflict of interest information missing from their original article. The conflict of interest statement for Dr. Robert Wenham has now been updated in the online version and can be found below:
- To determine the relationship between chemotherapy dose modification (dose adjustment or treatment delay), overall survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial ovarian carcinoma (EOC) and primary peritoneal carcinoma (PPC) who receive carboplatin and paclitaxel.
- Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a prediction model for R0 to support surgeons in their clinical care decisions.
- This study evaluated single nucleotide polymorphisms (SNPs) associated with progression free (PFS) and overall survival (OS) in patients with advanced stage serous EOC.
- Ovarian tumors are classified into three categories based on progenitor cell type: surface-epithelial, sex cord-stromal and germ cell neoplasms . Of these, epithelial ovarian cancers (EOCs which may, in fact, often originate from the fallopian tube) comprise the majority of cases, and these are usually diagnosed at an advanced stage with an associated poor prognosis. Serous epithelial ovarian carcinoma (SOC) is the most commonly observed subtype of EOC both in the United States  and worldwide [3,4].
- Predictive factors for efficacy of bevacizumab in advanced ovarian cancer have remained elusive. We investigated ascites both as a prognostic factor and as a predictor of efficacy for bevacizumab.